Praxis Investment Management Inc. Buys 3,150 Shares of Incyte Corporation $INCY

Praxis Investment Management Inc. raised its stake in Incyte Corporation (NASDAQ:INCY) by 82.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,980 shares of the biopharmaceutical company’s stock after purchasing an additional 3,150 shares during the period. Praxis Investment Management Inc.’s holdings in Incyte were worth $475,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Banque Transatlantique SA bought a new stake in Incyte in the first quarter valued at $26,000. Hilltop National Bank bought a new stake in shares of Incyte during the second quarter worth about $37,000. SVB Wealth LLC bought a new stake in shares of Incyte during the first quarter worth about $39,000. Geneos Wealth Management Inc. increased its position in shares of Incyte by 350.0% during the first quarter. Geneos Wealth Management Inc. now owns 756 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 588 shares in the last quarter. Finally, WPG Advisers LLC bought a new stake in shares of Incyte during the first quarter worth about $47,000. 96.97% of the stock is owned by institutional investors.

Insider Transactions at Incyte

In other Incyte news, EVP Steven H. Stein sold 3,706 shares of the company’s stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $67.94, for a total value of $251,785.64. Following the completion of the sale, the executive vice president directly owned 102,886 shares of the company’s stock, valued at approximately $6,990,074.84. This represents a 3.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 4,261 shares of company stock valued at $298,482. Corporate insiders own 17.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on INCY shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Incyte in a research report on Wednesday, October 8th. Bank of America boosted their target price on shares of Incyte from $90.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday, September 4th. Barclays started coverage on shares of Incyte in a research report on Friday, August 1st. They set an “overweight” rating and a $90.00 target price for the company. Wells Fargo & Company raised shares of Incyte from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $67.00 to $89.00 in a research report on Wednesday, August 6th. Finally, Truist Financial boosted their target price on shares of Incyte from $73.00 to $79.00 and gave the stock a “hold” rating in a research report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Incyte currently has an average rating of “Hold” and an average price target of $84.79.

Incyte Trading Up 0.3%

Shares of INCY stock opened at $87.57 on Friday. Incyte Corporation has a 52-week low of $53.56 and a 52-week high of $92.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.78 and a current ratio of 2.85. The company has a 50-day simple moving average of $85.20 and a two-hundred day simple moving average of $72.54. The company has a market capitalization of $17.10 billion, a price-to-earnings ratio of 19.90, a PEG ratio of 0.68 and a beta of 0.73.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.